Abstract
Treatment of male hypogonadism with testosterone (T), most profoundly with long-acting injections and pellets, have been shown to inhibit the hypogonadal-pituitary-gonadal (HPG) axis4. T injections result in a reduction in both luteinizing hormone (LH) and follicle stimulating hormone (FSH) concentrations to undetectable levels as quickly as 2 weeks following initiation of therapy5. The decrease in LH and FSH impairs critical components of spermatogenesis. In a phase 3 study of an oral testosterone undecanoate (TU) capsule (JATENZO®), complete suppression of LH and FSH concentrations was not observed in all men6, although the impact on gonadotropin suppression by age was not studied.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
